Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior ...

Sellas Life Sciences has dosed the first paediatric subject with acute myeloid leukaemia (AML) in its multi-centre Phase II ...

Here, the authors show that phosphorylation of Cdk1 substrates is influenced by a phosphate-binding pocket on the surface of the cyclin regulatory subunit. Dormant replication origins begin DNA ...

Researchers have introduced DiffSMol, a generative AI model capable of generating realistic 3D structures of small molecules ...

Press Release Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been ...

Using advanced artificial intelligence, researchers have developed a novel method to make drug development faster and more ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 5.56%, which has investors questioning if this is right time ...

Interestingly, some viral protein kinases in herpesviruses are structurally conserved and mimic human cyclin-dependent kinases (CDKs). Herpes simplex virus 2 (HSV-2) causes skin and genital ...

The company's lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin ...